HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
NCT05751044 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 26
Last updated 2025-09-16
Summary
HEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed/refractory (R/R) ALL and LBL. Sub-protocol B is a phase I/II trial evaluating the safety and efficacy of dasatinib + venetocolax in combination with dexamethasone + Cyclophosphamide and cytarabine in children and AYA with R/R ped ALL/LBL whose tumor present with alterations in the MAPK/SRC pathway.
Conditions
- Acute Lymphoblastic Leukemia
- Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent
- Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent
- Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
- Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
Interventions
- DRUG
-
Oral
- DRUG
-
oral
- DRUG
-
oral/intervenous
- DRUG
-
intravenous
- DRUG
-
intravenous
- DRUG
-
intrathecal chemotherapy
IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement
Sponsors & Collaborators
-
Innovative Therapies For Children with Cancer Consortium
collaborator OTHER -
IBFM
collaborator INDUSTRY -
Fight Kids Cancer
collaborator OTHER -
Princess Maxima Center for Pediatric Oncology
lead OTHER
Principal Investigators
-
Michel Zwaan, Prof. Dr. · Princess Máxima Center
-
Andrej Lissat, MD PhD · Charite University, Berlin, Germany
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 1 Year
- Max Age
- 21 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-10-01
- Primary Completion
- 2032-02-01
- Completion
- 2032-02-01
Countries
- Austria
- Belgium
- Denmark
- Finland
- France
- Germany
- Ireland
- Israel
- Italy
- Netherlands
- Norway
- Spain
- Sweden
- United Kingdom
Study Locations
More Related Trials
-
International Study for Treatment of High Risk Childhood Relapsed ALL 2010
NCT03590171 ·Status: RECRUITING ·Phase: PHASE2
-
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
NCT04043494 ·Status: RECRUITING ·Phase: PHASE3
-
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
NCT06317662 ·Status: RECRUITING ·Phase: PHASE2
-
Pulses of Vincristine and Dexamethasone in BFM Protocols for Children With Acute Lymphoblastic Leukemia
NCT00411541 ·Status: COMPLETED ·Phase: PHASE4
-
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
NCT01700946 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
NCT05761171 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma
NCT03323034 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)
NCT03743246 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Venetoclax Basket Trial for High Risk Hematologic Malignancies
NCT05292664 ·Status: RECRUITING ·Phase: PHASE1
-
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
NCT02518750 ·Status: TERMINATED ·Phase: PHASE2
-
PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
NCT03817320 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma
NCT02227108 ·Status: TERMINATED ·Phase: PHASE2
-
Pemetrexed Disodium in Treating Young Patients With Recurrent Solid Tumors
NCT00070473 ·Status: COMPLETED ·Phase: PHASE1
-
Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia
NCT00022737 ·Status: COMPLETED ·Phase: PHASE3
-
International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010
NCT01802814 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage
NCT03194932 ·Status: COMPLETED ·Phase: PHASE1
-
B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021
NCT05518383 ·Status: RECRUITING ·Phase: PHASE4
-
Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors
NCT01141244 ·Status: COMPLETED ·Phase: PHASE1
-
Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma
NCT06620302 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
NCT01088763 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of Pemetrexed in Children With Recurrent Cancer
NCT00520936 ·Status: COMPLETED ·Phase: PHASE2
-
Study of mAb 216 With Chemotherapy for Treatment of Pediatric Relapsed or Refractory B-progenitor Acute Lymphoblastic Leukemia
NCT00313053 ·Status: TERMINATED ·Phase: PHASE1
-
Vorinostat in Children
NCT01422499 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Temozolomide in Treating Young Patients With Refractory or Recurrent Leukemia
NCT00083070 ·Status: COMPLETED ·Phase: PHASE1
-
Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT00186875 ·Status: COMPLETED ·Phase: PHASE2